SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media is trending amid heated discussions around freedom of speech and cancel culture, particularly following ABC's decision to pull "Jimmy Kimmel Live!" off the air after controversial comments about Charlie Kirk. The community is divided, with some decrying censorship and others criticizing what they see as weaponizing the FCC. Broader context includes ongoing debates about political polarization and media bias.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla's stock is trending amid discussions around potential rate cuts and their impact on the company, with some traders anticipating a breakout while others remain skeptical of the valuation and fundamentals. Community members are debating whether the recent price action is driven by genuine market forces or potential manipulation, particularly in light of Elon Musk's recent activity. Discussions also include future delivery numbers and potential for new revenue streams.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending as investors anticipate key announcements from the upcoming Meta Connect event, with community members actively discussing potential product releases and their impact on the stock. Some are also pointing to Meta's potential to capitalize on the AI infrastructure build-out. Additionally, there is speculation around Meta's involvement in a possible acquisition of TikTok.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending as it makes new all-time highs, driven by positive sentiment around its quantum computing technology and recent news, including a memorandum of understanding with the Department of Energy and the acquisition of Vector Atomic. The community is actively discussing its potential for a short squeeze, comparing it to other high-growth tech stocks, and debating its long-term valuation amid government contracts and expansion plans. While some express concern over profitability and valuation, others see it as a long-term play with significant upside.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) is trending as the community rallies around its strong, decentralized foundation on the Bitcoin network, touting it as more than just a memecoin. There's excitement around potential listings on major exchanges like Coinbase, with some highlighting the growing collaboration between Dog and other entities like $CBLO. The #DOGXArmy is actively promoting its unique attributes, including a fair distribution and community-driven ethos.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The crypto "crow with knife" is trending as the community celebrates its recent listing on Coinbase. Community members are also excited about the project's fully circulated supply and cross-chain functionality, with many using the hashtag #cawcaw to show their support. Some users are also discussing the potential for the project to reach a wider audience.

TOSHI

TOSHI.X is trending due to recent listings on South Korean exchanges and Binance futures, sparking excitement about increased accessibility and potential for higher market capitalization. The community is actively discussing strategies to reach new all-time highs, comparing it to other meme coins like DOGE.X and SHIB.X, and anticipating further gains as Asian markets awaken.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum ($QBTS) is trending amid discussions about the quantum computing sector's potential and D-Wave's positioning within it, with community members highlighting its technology and potential for government contracts. Bullish sentiment is fueled by revenue growth, record cash, and a hybrid AI/quantum toolkit, while some traders discuss short squeeze possibilities and compare QBTS to other quantum stocks. Conversations also touch on valuation, potential news from upcoming conferences, and broader market factors like interest rate decisions.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as discussions revolve around the potential impact of their oral semaglutide (Wegovy pill) and its comparable weight-loss results to the injectable version, with many viewing it as a game changer; however, some traders express concerns over market share competition and side effect profiles relative to competitors. The community is also weighing recent job cuts and future growth prospects in light of increasing competition in the obesity treatment market, with some highlighting the company's long-term value.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as part of a broader rally in quantum computing stocks, with community members weighing the impact of recent partnerships and potential for future revenue. Discussions revolve around the company's technology, market positioning relative to competitors, and speculation about inclusion in potential US-UK tech agreements. Despite bullish sentiment, some traders are wary of the company's high valuation and stretched RSI.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Eli Lilly and Company (LLY) stated on Wednesday that its oral weight-loss drug was found to be superior to its rival Novo Nordisk’s (NVO) oral Semaglutide in a head-to-head late-stage trial.The study evaluated the safety and efficacy of Lilly’s Orforglipron in 1,698 adults with type 2 diabetes as compared to oral Semaglutide. At 52 weeks, Orforglipron met the primary as well as secondary endpoints across each dose comparison vs. oral Semaglutide, delivering greater improvements in average blood sugar levels and weight, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-superior-oral-semaglutide-head">said</a>.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LLY">LLY stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.Kenneth Custer, executive vice president and president of Lilly Cardiometabolic Health, said that in the trial, Orforglipron outperformed both doses of oral Semaglutide in reducing blood glucose levels. “At the highest dose, Orforglipron helped nearly three times as many participants reach near-normal blood sugar versus the highest dose of oral Semaglutide,” he said, while adding that head-to-head trials are a “gold standard for comparing potential treatments."The trial compared 12 mg and 36 mg of Orforglipron with 7 mg and 14 mg of oral Semaglutide. Orforglipron lowered blood glucose levels by as much as 2.2% compared to 1.4% with the highest dose of oral Semaglutide at 52 weeks. Notably, 37.1% of participants taking the highest dose of Orforglipron achieved a blood glucose level lower than 5.7% compared to 12.5% taking the highest dose of oral Semaglutide, Lilly said.Furthermore, participants taking Lilly’s drug achieved as much as a 9.2% reduction in weight from baseline, compared to 5.3% with oral Semaglutide, the company said. Orforglipron also showed clinically meaningful improvements across key cardiovascular risk factors, it added.Treatment discontinuation rates due to adverse events, however, were higher in the Orforglipron population, though the study was not powered to compare the safety and tolerability of Orforglipron and oral Semaglutide.Treatment discontinuation rates due to adverse events were 8.7% for 12 mg Orforglipron and 9.7% for 36 mg Orforglipron, as compared to 4.5% for 7 mg oral Semaglutide and 4.9% for 14 mg oral Semaglutide, Lilly said.The company expects to submit applications for Orforglipron for the treatment of type 2 diabetes to global regulatory agencies in 2026. Oral Semaglutide, meanwhile, is already approved for the treatment of type 2 diabetes under the name Rybelsus.LLY stock is down by 15% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-says-asthma-drug-failed-trial-in-smokers-disease/chDGnwkRd64">AstraZeneca Says Asthma Drug Failed Trial In Smoker’s Disease</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. (Photo by Scott Olson/Getty Images)

Eli Lilly Says Its Obesity Pill Topped Novo Nordisk’s Oral Drug In Late-Stage Diabetes Trial

At 52 weeks, Orforglipron met the primary and all key secondary endpoints across each dose comparison as compared to oral Semaglutide, delivering greater improvements in average blood sugar levels and weight, the company said.

Equity

At 52 weeks, Orforglipron met the primary and all key secondary endpoints across each dose comparison as compared to oral Semaglutide, delivering greater improvements in average blood sugar levels and weight, the company said.


AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?

Amgen's MariTide and Viking's VK2735 show promise in obesity, but pipeline strength and performance set the two biotech players apart.

The U.S. Food and Drug Administration has sent a letter to Novo Nordisk (NVO) CEO Maziar Mike Doustdar regarding the company’s promotional communication featuring Oprah Winfrey, alleging that the video is false or misleading.The video originally appeared on ABC as a Primetime Oprah Special on March 18, 2024. It also subsequently appeared on Hulu. The video is a 42-minute special program hosted by Oprah Winfrey, featuring patient testimonials from individuals who struggle with obesity and excessive weight, including those who have used Novo’s Wegovy, Ozempic, or Victoza.The FDA <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/novo-nordisk-inc-716495-09092025">alleged</a> in a letter dated September 9 that the video misbranded Novo’s Wegovy, Ozempic, and Victoza, making its distribution violative. The video was also not submitted at the time of initial dissemination or publication as required by law, the agency said.“These violations are concerning from a public health perspective because the promotional communication creates a misleading impression regarding the safety of Wegovy, Ozempic, and Victoza, which are drugs with multiple serious, potentially life-threatening risks,” the agency said.The FDA also noted that obesity and type 2 diabetes are significant public health concerns in the U.S., and consumers who seek medical treatment for these conditions should receive truthful and nonmisleading information regarding the serious risks associated with the use of the drugs. While Novo’s Wegovy is used for weight management, its Ozempic and Victoza are used to treat type 2 diabetes.The FDA said that several advisory comments dated as long back as 2010 addressed draft promotional communications for Victoza with certain similarities to the aforementioned video. The agency expressed concerns that <a href="https://stocktwits.com/symbol/NVO">Novo</a> is promoting the three drugs in a manner that fails to present the serious risks of these drug products in a truthful and nonmisleading manner, despite the FDA’s prior comments.While the video includes numerous representations of the benefits of Wegovy, Ozempic, and Victoza made by representatives of Novo Nordisk, it omits important risk information or minimizes the risks associated with these drug products, the FDA said. Only four minutes in total were devoted to the important risks associated with GLP-1 drugs, such as Wegovy, the FDA said.The video also omits reference to how the drugs are contraindicated in patients with a personal or family history of Medullary Thyroid Cancer or in patients with Multiple Endocrine Neoplasia syndrome type 2, it added. The omissions are exacerbated by statements from Amanda Velazquez, a paid consultant of Novo, made on the video, the FDA said.NVO stock is down by 33% this year and by 58% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-and-hers-stock-tumbles-7-percent-after-fda-letter/chwyNFWRdzV">Hims &amp; Hers Stock Draws Investor Attention After Tumbling 7% – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ozempic manufactured by Novo Nordisk packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on December 7, 2023. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

US FDA Alleges Novo Nordisk’s Video On Weight-loss Drugs Featuring Oprah Winfrey Is ‘False Or Misleading’ 

The FDA alleged in a letter dated September 9 that the video misbranded Novo’s Wegovy, Ozempic, and Victoza, making its distribution violative. 

Is ABBV Stock a Buy, Hold, or Sell After Its Almost 23% Rise YTD?

AbbVie surges 22.5% YTD as new drugs Skyrizi and Rinvoq drive growth, offsetting Humira losses and fueling long-term momentum.

Novo Nordisk (NVO) announced on Tuesday that its new obesity treatment, Cagrilintide, reduced body weight by 11.8% after 68 weeks in a late-stage study.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916427">reported</a> an average weight loss of 12.5 kg, compared to 2.5 kg with the placebo, in the trial evaluating the efficacy and safety of once-weekly Cagrilintide 2.4 mg monotherapy, plus lifestyle intervention, for adults with obesity or overweight and a weight-related comorbidity without diabetes. The above levels of weight reduction were observed in participants who adhered to the treatment. Regardless of adherence, average weight loss with Cagrilintide was 11.5% compared to 3.0% with placebo after 68 weeks.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVO">NVO stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels. Shares of the company traded over 2% higher at the time of writing.<figure class="image"><img style="aspect-ratio:575/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_16_at_9_59_21_AM_png_2efadb4b5b.webp" alt="NVO's Sentiment Meter and Message Volume as of 9:59 a.m. ET on Sept. 16, 2025 | Source: Stocktwits" width="575" height="60"><figcaption>NVO's Sentiment Meter and Message Volume as of 9:59 a.m. ET on Sept. 16, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed disappointment that the stock rallied only 2-3% on good news.<stembedurl>https://stocktwits.com/King990/message/628811943</stembedurl>Cagrilintide works differently from currently approved GLP-1-based treatments for weight loss, including Novo’s Wegovy and Eli Lilly’s Zepbound. The new drug mimics the naturally occurring hormone amylin that helps control blood glucose levels and appetite by slowing gastric emptying, reducing glucagon secretion, and promoting satiety.The company also stated that approximately one in three participants receiving Cagrilintide achieved 15% or more weight loss, compared to approximately one in 20 participants receiving a placebo, when patients adhered to the treatment.Novo stated that the drug was well-tolerated, while adding that the most common side effects were gastrointestinal, including nausea, vomiting, diarrhoea, and constipation. These side effects were mainly temporary and mild to moderate, and 1% of participants discontinued the study due to nausea, compared to 0.1% of participants who received a placebo.“We’re excited that these data, the first phase 3 data of a next-generation amylin therapy, show promise, and we look forward to further investigating cagrilintide’s potential in the dedicated phase 3 RENEW programme,” said Martin Holst Lange, chief scientific officer and executive vice president of Research and Development at Novo Nordisk.Another late-stage programme investigating the efficacy and safety of Cagrilintide in people with obesity or overweight is due to start in the fourth quarter of this year.Separately, Bloomberg <a target="_blank" rel="noopener noreferrer nofollow" href="https://bloomberg.com/news/articles/2025-09-16/novo-plans-to-seek-us-approval-for-its-high-dose-obesity-shot?sref&amp;#61;8QBk7toa">reported</a> on Tuesday that Novo plans to seek U.S. regulatory approval for a high-dose version of Wegovy. Though the drugmaker hasn’t yet formally announced its U.S. plans, it intends to file for the U.S. Food and Drug Administration approval, said Lange at the European Association for the Study of Diabetes conference in Vienna, according to the report.NVO stock is down 34% this year and by about 58% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-regulator-opens-probe-into-174000-plus-tesla-model-y-vehicles/chwyiNgRdz5">US Regulator Opens Probe Into 174,000-Plus Tesla Model Y Vehicles – Check Out Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Novo Nordisk Says New Obesity Treatment Achieved 11.8% Body Weight Reduction In Late-Stage Study

The company reported an average weight loss of 12.5 kg, compared to 2.5 kg with the placebo, in a trial evaluating the efficacy and safety of once-weekly Cagrilintide 2.4 mg monotherapy. 

Will Rybelsus' Updated EU Label Propel Fresh Growth Potential for NVO?

Novo Nordisk gains EU approval for adding the cardiovascular indication to Rybelsus' label, strengthening its edge in the competitive diabetes market.

Lilly Moves Past 50-Day SMA: Should You Consider Buying the Stock Now?

Eli Lilly shares move past the 50-day SMA as weight-loss drug data, rising sales and pipeline momentum fuel optimism.

Eli Lilly (LLY) and Novo Nordisk (NVO) are reportedly expected to launch oral obesity pills by next year once they get regulatory approval in the U.S.According to a CNBC report, which cited an interview with Lilly’s Chief Scientific Officer, Dan Skovronsky, the company anticipates receiving results in the next few months from a head-to-head trial between its oral drug, Orforglipron, and Novo Nordisk’s oral Semaglutide. Daily pills would likely bring GLP-1s to more people, the report stated.&nbsp;The report noted that the primary aim of the study is to assess the effectiveness of the pills in lowering blood sugar levels in individuals with Type 2 diabetes, while also monitoring their impact on weight loss.“We wouldn’t have undertaken this head-to-head phase three randomized control trial unless we had a lot of confidence that orforglipron would fare well in comparison to oral semaglutide,” Skovronsky told CNBC.Retail sentiment on <a href="https://stocktwits.com/symbol/LLY">Eli Lilly</a> remained unchanged in the ‘neutral’ territory, with message volumes at ‘low’ levels, according to Stocktwits data.The report said that Skovronsky noted the results across trials, which did not directly compare the two drugs, should not be made, given Novo’s pill appears more effective with fewer discontinuations.&nbsp;Meanwhile, Novo’s Chief Scientific Officer, Martin Holst Lange, told CNBC in another interview that the data speaks for itself.Retail sentiment on <a href="https://stocktwits.com/symbol/NVO">Novo</a> remained in the ‘bearish’ territory, with chatter at ‘low’ levels, according to data from Stocktwits.The report explained that Novo’s upcoming obesity pill is a tablet form of its weekly injection, Wegovy. In contrast, Lilly’s pill, Orforglipron, is a completely new drug and different from its injectable treatment, Zepbound. According to Skovronsky, Zepbound remains the benchmark for effectiveness, helping patients lose over 20% of their body weight.The CNBC report noted that neither Novo’s pill nor Lilly’s oral drug is as effective as Zepbound. It added that Orforglipron&nbsp;has achieved around 12% weight loss at its highest dose, while oral Semaglutide&nbsp;has reached about 17%, prompting uncertainty over how many patients will choose a pill if it delivers less weight loss than injectable options.Skovronsky told CNBC that pills could eventually become the primary way that obesity would be treated, and that oral drugs could have a larger market share than shots.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/rh-stock-sees-slew-price-target-cuts-from-wall-street-as-trump-tariffs-bite/chw8MrGRdDN">RH Stock Sees Slew Of Downgrades, Price Target Cuts From Wall Street As Trump Tariffs Bite</a>

While Lilly’s broader portfolio spans diabetes, cancer, and neuroscience treatments, investors remain largely focused on Mounjaro and Zepbound. 

Eli Lilly, Novo Nordisk Preparing To Introduce Obesity Pills Next Year In The US: Report

According to a CNBC report, which cited an interview with Lilly’s Chief Scientific Officer, Dan Skovronsky, the company expects trial results within months from a direct comparison between its oral drug Orforglipron and Novo Nordisk’s Semaglutide.

According to a CNBC report, which cited an interview with Lilly’s Chief Scientific Officer, Dan Skovronsky, the company anticipates receiving results in the next few months from a head-to-head trial between its oral drug, Orforglipron, and Novo Nordisk’s oral Semaglutide. 

Where Does VKTX Stock Stand After the Obesity Pill Setback?

Viking Therapeutics faces pressure after mixed oral obesity pill trial results, raising safety concerns but still meeting key study goals.

Prothena Down 40% Year to Date: What Lies Ahead for the Stock? 

Prothena stock tumbles 40% year to date due to pipeline setbacks, though its partnered programs with Roche and Novo Nordisk still show potential.

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

Current Price	$60.30
Prev Close	$57.20
Open	$57.78
Dividend Yield	1.37%
50-Day Moving Average	$57.47
Beta	0.61
Avg. Volume	19.92M
PE Ratio	16.01

52-Week High	$135.20
52-Week Low	$45.05
Market Capitalization	$195.91B
EPS (Annual)	$3.29
Price to Book	9.77
Revenue Per Employee	$551,951.47
Enterprise Value/EBITDA	N/A

NVO
Novo Nordisk A/S

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NVO News

NVO Novo Nordisk A/S